Find verified Ripretinib API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Ripretinib for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Ripretinib API.
Alternate Names: qinlock, ripretinibum, DCC2618
CAS No: 1442472-39-0
PubChem CID: 71584930
Mol Formula: C24H21BrFN5O2
Mol Weight: 510.4 g/mol
IUPAC Name: 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea
API Description: Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.
